嵌合抗原受体修饰的 T 细胞治疗急性髓系白血病。

Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia.

机构信息

Institute of Biomedical Engineering and Technology, Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, NO. 3663 Zhongshan Road, Shanghai, 200062, People's Republic of China.

China Novartis Institutes for Biomedical Research Co., Ltd., GDD/TRD/Chemical and Pharmaceutical Profiling, 5F, Building 3, Novartis Campus 4218 Jinke Rd, Zhangjiang Hi-Tech Park Pudong District, Shanghai, 201203, China.

出版信息

J Hematol Oncol. 2017 Aug 29;10(1):151. doi: 10.1186/s13045-017-0519-7.

DOI:10.1186/s13045-017-0519-7

PMID:28851445

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5576380/

Abstract

Currently, conventional therapies for acute myeloid leukemia (AML) have high failure and relapse rates. Thus, developing new strategies is crucial for improving the treatment of AML. With the clinical success of anti-CD19 chimeric antigen receptor (CAR) T cell therapies against B-lineage malignancies, many studies have attempted to translate the success of CAR T cell therapy to other malignancies, including AML. This review summarizes the current advances in CAR T cell therapy against AML, including preclinical studies and clinical trials, and discusses the potential AML-associated surface markers that could be used for further CAR technology. Finally, we describe strategies that might address the current issues of employing CAR T cell therapy in AML.

摘要

目前，急性髓细胞白血病（AML）的常规疗法失败率和复发率很高。因此，开发新策略对于改善 AML 的治疗至关重要。随着抗 CD19 嵌合抗原受体（CAR）T 细胞疗法在 B 细胞恶性肿瘤中的临床成功，许多研究试图将 CAR T 细胞疗法的成功转化为其他恶性肿瘤，包括 AML。本综述总结了针对 AML 的 CAR T 细胞疗法的最新进展，包括临床前研究和临床试验，并讨论了可用于进一步 CAR 技术的潜在 AML 相关表面标志物。最后，我们描述了可能解决当前 AML 中使用 CAR T 细胞疗法的问题的策略。